JeanMarie Geunot’s Maverick Therapeutics Partners With Takeda Pharmaceutical Company
Maverick Therapeutics, one of MPM’s Capital Portfolio Companies, has announced its partnership with Takeda Pharmaceutical Company Limited. The partnership will see both parties work together on a new improved form of T-Cell engagement therapies. Jeanmarie Guenot, Patrick Baeuerle and Luke Evnin, the founder of MPM, founded maverick Therapeutics, a startup biotechnology company, in 2016. Over the years, Maverick has been developing antibodies. The new partnership will enable Maverick to develop smaller and customizable T-Cell engagement therapies at https://www.linkedin.com/in/jeanmarie-guenot-4a140617. In addition, the $125 million partnership gives Takeda Company the right to purchase Maverick after 5 years.
About JeanMarie Guenot
JeanMarie Guenot is the CEO Amphivena Therapeutics, Inc., an innovative company that engages in the development of cancer therapies. For over two decades, Guenot has gained immense experience and knowledge in the pharmaceutical and biotechnology industry. Through her visionary and transformative leadership style, she has managed to enhance the company’s growth. JeanMarie is highly trained in physical and medicinal chemistry. She is an alumnus of the University of California and Wharton School at the University of Pennsylvania where she earned her PhD and MBA respectively. Her entrepreneurial career started at Atlas Venture where she founded her life science companies while she managed venture capital investments.
As a scientist, Guenot worked for Preclinical R&D at Hoffman-La Roche. Her boundless career saw her serve in different capacities for various companies, including private to public entities, pharmaceutical R&D, corporate and commercial corporations, venture capital, as well as project and alliance management. JeanMarie served as a vice president of PDL BioPharma before establishing SKS Ocular. This ophthalmic company focused on dry AMD besides releasing treatments and technologies for glaucoma, macular degeneration and ocular inflammation.
In her career, Guenot has entered into different partnerships with the objective of developing cancer drugs. In 2015, JeanMarie Guenot led the partnership between Amphivena and Janssen Biotech in the clinical investigation of undisclosed tumor antigen. Johnson and Johnson Innovation facilitated this process on amphivena.com. It aimed at advancing the development of therapies for hematologic malignancies. The success of this partnership was a major milestone for Amphivena. Guenot has specialized skills in oncology, neurology, autoimmunity and cardiovascular disorders and ophthalmic diseases.